C-C5-05: Genetic Risk Factors: Idiopathic Thrombocytopenic Purpura following the First Dose of Measles-Mumps-Rubella Vaccination in Children

Background Immune thrombocytopenic purpura (ITP) is a rare though well recognized adverse event following measles, mumps, and rubella (MMR) vaccine. Identification of individuals at high risk for these and other vaccine adverse events might inform pre-vaccination screening options for the future. Working in close collaboration with the FDA, we seek to identify genetic differences underlying the susceptibility to ITP following MMR or MMR and varicella (MMRV) vaccination. We will compare the genetic make-up of these cases to ITP occurring after medication exposure and to idiopathic cases of ITP.